



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
20.04.2022 Bulletin 2022/16

(45) Date of publication and mention
of the grant of the patent:
16.02.2022 Bulletin 2022/07

(21) Application number: **13777258.8**

(22) Date of filing: **10.10.2013**

(51) International Patent Classification (IPC):
A61K 9/00 ^(2006.01) **A61K 47/64** ^(2017.01)
A61K 47/69 ^(2017.01)

(52) Cooperative Patent Classification (CPC):
A61K 47/6425; A61K 9/0085; A61K 47/6907

(86) International application number:
PCT/EP2013/071178

(87) International publication number:
WO 2014/057043 (17.04.2014 Gazette 2014/16)

(54) **COMPOSITION AND DELIVERY VEHICLE FOR ACTIVE AGENTS AND METHODS THEREFOR**
ZUSAMMENSETZUNG UND FREISETZUNGSVEHIKEL FÜR WIRKSTOFFE SOWIE VERFAHREN
DAFÜR

COMPOSITION ET VÉHICULE DE DÉLIVRANCE POUR AGENTS ACTIFS ET PROCÉDÉS
ASSOCIÉS

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **12.10.2012 US 201213650193**

(43) Date of publication of application:
26.08.2015 Bulletin 2015/35

(73) Proprietors:
• **Steinfeld, Robert**
8708 Männedorf (CH)
• **Allorphan UG**
37075 Göttingen (DE)

(72) Inventors:
• **STEINFELD, Robert**
37077 Göttingen (DE)
• **GRAPP, Marcel**
37083 Göttingen (DE)

(74) Representative: **Kröncke, Rolf et al**
Gramm, Lins & Partner
Patent- und Rechtsanwälte PartGmbB
Freundallee 13 a
30173 Hannover (DE)

(56) References cited:
EP-A1- 2 425 817 WO-A1-2010/143193
WO-A1-2011/097480

- **GUNTER MÜLLER: "Microvesicles/exosomes as potential novel biomarkers of metabolic diseases", DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY, 1 August 2012 (2012-08-01), page 247, XP55089998, DOI: 10.2147/DMSO.S32923**
- **ROBERT STEINFELD ET AL: "Folate Receptor Alpha Defect Causes Cerebral Folate Transport Deficiency: A Treatable Neurodegenerative Disorder Associated with Disturbed Myelin Metabolism", THE AMERICAN JOURNAL OF HUMAN GENETICS, vol. 85, no. 3, 1 September 2009 (2009-09-01), pages 354-363, XP55090002, ISSN: 0002-9297, DOI: 10.1016/j.ajhg.2009.08.005**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- Todd A Patrick ET AL: "Folate receptors as potential therapeutic targets in choroid plexus tumors of SV40 transgenic mice", Journal of Neuro-Oncology, 1 April 1997 (1997-04-01), pages 111-123, XP55090006, Boston DOI: 10.1023/A:1005713115147 Retrieved from the Internet:
URL: <http://www.ncbi.nlm.nih.gov/pubmed/9120540>-Use of folate receptors as potential therapeutic targets in hte brain.
- LYDIA ALVAREZ-ERVITI ET AL: "Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes", NATURE BIOTECHNOLOGY, vol. 29, no. 4, 20 March 2011 (2011-03-20) , pages 341-345, XP55089953, ISSN: 1087-0156, DOI: 10.1038/nbt.1807